Showing 1901-1910 of 2526 results for "".
- Nanodropper Launches 2022 Give the Gift of Vision Campaign to Support Global Access to Eye Carehttps://modernod.com/news/nanodropper-launches-2022-give-the-gift-of-vision-campaign-to-support-global-access-to-eye-care/2481193/Nanodropper launched its "2022 Give the Gift of Vision" program, an effort to donate 1,000 Nanodropper adaptors to at-need patients in the United States and its global nonprofit partners—designed to deliver better access to vision-saving care in low resource settings in
- LSU Health New Orleans Develops New Human Cell Line to Study Blinding Eye Disordershttps://modernod.com/news/lsu-health-new-orleans-develops-new-human-cell-line-to-study-blinding-eye-disorders/2481175/Under the direction of Boyd Professor Nicolas Bazan, MD, PhD, scientists at LSU Health New Orleans Neuroscience Center of Excellence have developed a new, experimental human cell line from retinal pigment epithelial cells. Called ABC, these cells so closely resemble and retain the properties of n
- Survey Identifies Diabetic Retinopathy Screening and Care as Top Outreach Eye Care Need in Utahhttps://modernod.com/news/survey-identifies-diabetic-retinopathy-screening-and-care-as-top-outreach-eye-care-need-in-utah/2481172/A recent survey of eye care providers and stakeholders identified screening and care for diabetes-related vision loss as the most urgent need for residents on the Navajo Nation, people experiencing homelessness, former refugees, and underinsured or uninsured Utahns, according to a team of health
- Researchers Discover New Molecular Driver of Retinoblastomahttps://modernod.com/news/researchers-discover-new-molecular-driver-of-retinoblastoma/2481163/Despite decades of medical advances, children who develop the pediatric eye cancer retinoblastoma often lose their vision or an eye due to a lack of specific, targeted therapies and a poor molecular understanding of the cancer. Now researchers at UT Southwestern and the University of Miami have <
- ImprimisRx Launches Fortisite (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulationhttps://modernod.com/news/imprimisrx-launches-fortisite-tobramycin-15-vancomycin-5-compounded-antibiotic-formulation/2481135/ImprimisRx announced the availability of Fortisite, which includes a patent-pending compounded combination of Tobramycin 1.5% and Vancomycin 5%. Compounded topical antibiotic formulations may be appropriate to prescribe for patients with clinical needs that are unmet by FDA-
- Outlook Therapeutics and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMDhttps://modernod.com/news/outlook-therapeutics-and-amerisourcebergen-announce-strategic-commercialization-agreement-for-ons-5010-for-the-treatment-of-wet-amd/2481116/Outlook Therapeutics and AmerisourceBergen, a specialty pharmaceutical distribution company, announced that they have entered into a strategic relationship in preparation for the anticipated commercial launch in the United States of ONS-5010/Lytenava (bevacizumab-vikg), if app
- Bausch + Lomb Sponsored Visionary Report Spotlights Nation's 'Blind Spots' on AMDhttps://modernod.com/news/bausch-lomb-sponsored-visionary-report-spotlights-nations-blind-spots-on-amd/2481091/Bausch + Lomb released a report of survey results from the company’s first Visionary Report, which was designed to identify new key insights into the value Americans place on their eyesight, as well as the ‘blind spots’ that may exist in the understanding and aware
- Trukera Medical Launches ScoutPro Osmolarity Systemhttps://modernod.com/news/trukera-medical-launches-new-scoutpro-osmolarity-system/2481081/Trukera Medical unveiled the first product under the new company name, the ScoutPro Osmolarity System. Designed to help advance corneal health decisions for busy eye care practices, ScoutPro is the first and only portable osmometer in the United States. The launch comes a wee
- Cellusion and Celregen Enter into License Agreement of CLS001 for a Corneal Endothelial Cell Regenerative Therapy in the Greater Chinahttps://modernod.com/news/cellusion-and-celregen-enter-into-license-agreement-of-cls001-for-a-corneal-endothelial-cell-regenerative-therapy-in-the-greater-china/2481079/Cellusion, a Japanese regenerative medicine startup, and Hangzhou Celregen Therapeutics, a member of Shanghai Fosun Pharmaceutical, announced an exclusive license agreement in the Greater China region for Celregen to develop, manufacture and commercialize CLS001. Under the agr
- Lensar Announces Application for Certification of the ALLY Adaptive Cataract Treatment System in the EUhttps://modernod.com/news/lensar-announces-application-for-certification-of-the-ally-adaptive-cataract-treatment-system-in-the-eu/2481069/Lensar announced the application for certification of the ALLY Adaptive Cataract Treatment System in the European Union. “Following the FDA clearance of ALLY in June 2022 and recent US commercial launch, this is another important step in our effort to bring ALLY to